Our Company

Vassilis Tsatsaris, MD, PhD, EMBA

Member
ObsEva Scientific Advisory Board

Gynaecologist-Obstetrician, Maternité Port-Royal, Hôpital Cochin, Paris – INSERM Unit U767 «Normal and Pathological Pregnancy», University Paris Descartes.

Vassilis Tsatsaris is Professor of Obstetrics and Gynaecology in the Department of Obstetrics and Gynecology at the Port-Royal Hôpital Cochin in Paris. He is specialised in fetal and maternal medicine and also holds a research position in the INSERM. His main research interests are preterm delivery, preeclampsia, intrauterine growth restriction (IUGR) and the physiology of utero-placental vascularisation.

In 2007, he helped found the PremUP foundation (www.premup.org), which aims to reduce preterm deliveries and their postnatal consequences. He is a member of the executive committee and the board of directors of the foundation. He is also a member of iLUMENS (Laboratory for teaching with simulation and innovating technologies), the French National Federation of Fetal Medicine Centres and of the French national college of Obstetrics and Gynecology.

Professor Tsatsaris has published more than 150 articles in national and international journals.

Are you sure you want to leave ObsEva.com?

We're sorry to see you go.
Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue